CAMBRIDGE, Mass. January 6, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced it will present at the JP Morgan 40th Annual...
